Free Trial

Brokers Offer Predictions for LRMR Q2 Earnings

Larimar Therapeutics logo with Medical background

Larimar Therapeutics, Inc. (NASDAQ:LRMR - Free Report) - Equities research analysts at Wedbush issued their Q2 2026 earnings estimates for Larimar Therapeutics in a report issued on Wednesday, April 30th. Wedbush analyst L. Chico anticipates that the company will earn ($0.41) per share for the quarter. The consensus estimate for Larimar Therapeutics' current full-year earnings is ($1.15) per share. Wedbush also issued estimates for Larimar Therapeutics' Q3 2026 earnings at ($0.45) EPS, Q4 2026 earnings at ($0.48) EPS, FY2028 earnings at $0.75 EPS and FY2029 earnings at $4.83 EPS.

LRMR has been the topic of a number of other research reports. Truist Financial began coverage on shares of Larimar Therapeutics in a research report on Wednesday, January 29th. They issued a "buy" rating and a $18.00 price objective on the stock. Guggenheim reiterated a "buy" rating and issued a $26.00 price objective on shares of Larimar Therapeutics in a research report on Tuesday, March 25th. Citigroup reissued a "buy" rating on shares of Larimar Therapeutics in a report on Tuesday, March 25th. HC Wainwright boosted their price objective on Larimar Therapeutics from $15.00 to $16.00 and gave the stock a "buy" rating in a research note on Tuesday, March 25th. Finally, Robert W. Baird cut their price objective on Larimar Therapeutics from $13.00 to $10.00 and set an "outperform" rating for the company in a research report on Tuesday, March 25th. Nine equities research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company's stock. According to MarketBeat, the company currently has a consensus rating of "Buy" and an average price target of $19.63.

View Our Latest Research Report on Larimar Therapeutics

Larimar Therapeutics Trading Up 4.5 %

Shares of LRMR traded up $0.10 during trading hours on Friday, reaching $2.20. 951,250 shares of the company traded hands, compared to its average volume of 739,359. The stock's fifty day moving average price is $2.34 and its 200 day moving average price is $4.15. Larimar Therapeutics has a 12-month low of $1.61 and a 12-month high of $11.20. The firm has a market cap of $140.54 million, a price-to-earnings ratio of -1.90 and a beta of 0.93.

Larimar Therapeutics (NASDAQ:LRMR - Get Free Report) last issued its quarterly earnings data on Wednesday, April 30th. The company reported ($0.46) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.42) by ($0.04).

Institutional Inflows and Outflows

Large investors have recently made changes to their positions in the stock. Jane Street Group LLC lifted its position in Larimar Therapeutics by 80.1% in the 3rd quarter. Jane Street Group LLC now owns 113,783 shares of the company's stock valued at $745,000 after acquiring an additional 50,622 shares in the last quarter. Barclays PLC boosted its holdings in Larimar Therapeutics by 321.2% during the third quarter. Barclays PLC now owns 60,032 shares of the company's stock worth $393,000 after purchasing an additional 45,781 shares during the last quarter. Virtu Financial LLC acquired a new stake in Larimar Therapeutics in the 3rd quarter valued at $71,000. Franklin Resources Inc. boosted its stake in shares of Larimar Therapeutics by 21.9% during the 3rd quarter. Franklin Resources Inc. now owns 19,723 shares of the company's stock worth $143,000 after buying an additional 3,549 shares during the last quarter. Finally, JPMorgan Chase & Co. grew its holdings in shares of Larimar Therapeutics by 18.7% in the 3rd quarter. JPMorgan Chase & Co. now owns 21,771 shares of the company's stock valued at $143,000 after acquiring an additional 3,425 shares in the last quarter. Institutional investors and hedge funds own 91.92% of the company's stock.

Larimar Therapeutics Company Profile

(Get Free Report)

Larimar Therapeutics, Inc, a clinical-stage biotechnology company, focuses on developing treatments for rare diseases using its novel cell penetrating peptide technology platform. Its lead product candidate is CTI-1601, which is in Phase 2 OLE clinical trial for the treatment of Friedreich's ataxia, a rare, progressive and fatal genetic disease.

See Also

Earnings History and Estimates for Larimar Therapeutics (NASDAQ:LRMR)

Should You Invest $1,000 in Larimar Therapeutics Right Now?

Before you consider Larimar Therapeutics, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Larimar Therapeutics wasn't on the list.

While Larimar Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

5G Stocks: The Path Forward is Profitable Cover

Enter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.

Get This Free Report
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

NVIDIA Earnings Preview: HUGE Stock Move Ahead
These 5 Small Stocks Could Deliver Huge Returns
ACT FAST! Congress Is POURING Into This Stock

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines